Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Core Insights - The company achieved 18% organic growth in Q3, with double-digit growth across all franchises [1] - Strong performance was noted across customer segments, including pharma, CDMO, and emerging biotech, which experienced growth for the first time [1] - Key standout products included the Protein segment and the Analytics business, both showing significant growth in Q3 [1]